BSACI 2021 guideline for the management of egg allergy
Leech C S ,Ewan W P ,Skypala J I et al ,15 August 2021 ,BSACI 2021 guideline for the management of egg allergy ,Clinical and Experimental Allergy ,doi: https://doi.org/10.1111/cea.14009
Abstract:
This guideline advises on the management of patients with egg allergy. Most com-monly egg allergy presents in infancy, with a prevalence of approximately 2% in chil-dren and 0.1% in adults. A clear clinical history will confirm the diagnosis in most cases. Investigation by measuring egg- specific IgE (by skin prick testing or specific IgE assay) is useful in moderate- severe cases or where there is diagnostic uncertainty. Following an acute allergic reaction, egg avoidance advice should be provided. Egg allergy usually resolves, and reintroduction can be achieved at home if reactions have been mild and there is no asthma. Patients with a history of severe reactions or asthma should have reintroduction guided by a specialist. All children with egg allergy should receive the MMR vaccine. Most adults and children with egg allergy can receive the influenza vaccine in primary care, unless they have had anaphylaxis to egg requiring intensive care support. Yellow Fever vaccines should only be consid-ered in egg- allergic patients under the guidance of an allergy specialist. This guide-line was prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI) and is intended for allergists and others with a special interest in allergy. The recommendations are evidence based. Where evidence was lacking, consensus was reached by the panel of specialists on the com-mittee. The document encompasses epidemiology, risk factors, diagnosis, treatment, prognosis and co- morbid associations